Virus therapy takes on bladder cancer in early trial

NCT ID NCT07359235

Recruiting now Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a modified virus called KD01, given directly into the bladder, to see if it is safe and can fight bladder cancer. The study includes 29 patients with either high-risk non-muscle-invasive bladder cancer or muscle-invasive bladder cancer. Some patients also receive an immunotherapy drug called AK104. The goal is to find the right dose and check for side effects and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KD01 (a modified virus that targets and kills cancer cells) and AK104 (an immunotherapy drug) in some patients
What this could lead to: If successful, this could point toward a new treatment option for bladder cancer that uses a virus to attack tumors directly.
What could go wrong: This is a very early Phase 1 trial with only 29 participants, so safety and effectiveness are not yet proven. The virus may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER (BC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma non-invasive bladder urothelial carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER (BC)

Contacts and locations

Locations

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430074, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.